行情

BMRN

BMRN

拜玛林制药
NASDAQ

实时行情|Nasdaq Last Sale

74.21
+1.56
+2.15%
盘后: 74.21 0 0.00% 16:00 09/16 EDT
开盘
72.29
昨收
72.65
最高
74.41
最低
72.01
成交量
95.66万
成交额
--
52周最高
106.74
52周最低
70.82
市值
133.18亿
市盈率(TTM)
-120.1781
分时
5日
1月
3月
1年
5年

分析师评级

23位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

BMRN 新闻

  • Stocks That Fell to 3-Year Lows in the Week of Sept. 13
  • GuruFocus.com.1天前
  • BioMarin Pharmaceutical (BMRN) Presents At Morgan Stanley 17th Annual Global Healthcare Conference - Slideshow
  • Seeking Alpha - Article.3天前
  • Is BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Overpaying Its CEO?
  • Simply Wall St..3天前
  • BioMarin to Participate in Morgan Stanley 17th Annual Global Healthcare Conference on September 10, 2019 in New York
  • PR Newswire.6天前

更多

所属板块

制药
-0.45%
制药与医学研究
-0.17%

热门股票

名称
价格
涨跌幅

BMRN 简况

BioMarin Pharmaceutical Inc. is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company's therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A). The Company is conducting clinical trials on various product candidates for the treatment of various diseases. Its clinical product candidates include Brineura, pegvaliase, vosoritide, BMN 270 and BMN 250.
展开

Webull提供BioMarin Pharmaceutical Inc.的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。